Exhibits |
||
99.1 |
||
99.2 |
||
99.3 |
||
101.INS |
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH |
INLINE XBRL Taxonomy Extension Schema Document. | |
101.DEF |
INLINE XBRL Taxonomy Extension Calculation Linkbase Document. | |
101.CAL |
INLINE XBRL Taxonomy Extension Definition Linkbase Document. | |
101.LAB |
INLINE XBRL Taxonomy Extension Label Linkbase Document. | |
101.PRE |
INLINE XBRL Taxonomy Extension Presentation Linkbase Document. | |
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |
NuCana plc | ||
By: |
/s/ Donald Munoz | |
Name: |
Donald Munoz | |
Title: |
Chief Financial Officer | |
For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||||||
Notes |
£ |
£ |
£ |
£ |
||||||||||||||||
| Research and development expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
| Administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
| Net foreign exchange gains (losses) |
( |
) | ( |
) | ||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||||||
| Operating loss |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||
| Finance income |
||||||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||||||
| Loss before tax |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||
| Income tax credit |
3 | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||||||
| Loss for the period |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||||||
| Basic and diluted loss per share |
4 | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||
For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
(in thousands) |
||||||||||||||||
£ |
£ |
£ |
£ |
|||||||||||||
| Loss for the period |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| Other comprehensive income (expense): |
||||||||||||||||
| Items that may be reclassified subsequently to profit or loss: |
||||||||||||||||
| Exchange differences on translation of foreign operations |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Other comprehensive income (expense) for the period |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total comprehensive loss for the period |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Attributable to: |
||||||||||||||||
| Equity holders of the Company |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
June 30, 2022 |
December 31, 2021 |
|||||||||||
(in thousands) |
||||||||||||
Notes |
£ |
£ |
||||||||||
| Assets |
||||||||||||
| Non-current assets |
||||||||||||
| Intangible assets |
5 | |||||||||||
| Property, plant and equipment |
||||||||||||
| Deferred tax asset |
3 | |||||||||||
| Other non-current assets |
6 | |||||||||||
| |
|
|
|
|||||||||
| |
|
|
|
|||||||||
| Current assets |
||||||||||||
| Prepayments, accrued income and other receivables |
||||||||||||
| Current income tax receivable |
3 | |||||||||||
| Cash and cash equivalents |
7 | |||||||||||
| |
|
|
|
|||||||||
| |
|
|
|
|||||||||
| Total assets |
||||||||||||
| |
|
|
|
|||||||||
| Equity and liabilities |
||||||||||||
| Capital and reserves |
||||||||||||
| Share capital and share premium |
9 | |||||||||||
| Other reserves |
||||||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||||||
| |
|
|
|
|||||||||
| Total equity attributable to equity holders of the Company |
||||||||||||
| |
|
|
|
|||||||||
| Non-current liabilities |
||||||||||||
| Provisions |
||||||||||||
| Lease liabilities |
||||||||||||
| |
|
|
|
|||||||||
| |
|
|
|
|||||||||
| Current liabilities |
||||||||||||
| Trade payables |
||||||||||||
| Payroll taxes and social security |
||||||||||||
| Accrued expenditure |
||||||||||||
| Lease liabilities |
||||||||||||
| |
|
|
|
|||||||||
| Total liabilities |
||||||||||||
| |
|
|
|
|||||||||
| Total equity and liabilities |
||||||||||||
| |
|
|
|
|||||||||
For the Six Months Ended June 30, |
||||||||||||||||||||||||||||||||
Share capital |
Share premium |
Own share reserve |
Share option reserve |
Foreign currency translation reserve |
Capital reserve |
Accumulated deficit |
Total equity attributable to equity holders |
|||||||||||||||||||||||||
(in thousands) |
||||||||||||||||||||||||||||||||
£ |
£ |
£ |
£ |
£ |
£ |
£ |
£ |
|||||||||||||||||||||||||
| Balance at January 1, 2021 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
| Loss for the period |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Other comprehensive expense for the period |
— | — | — | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total comprehensive loss for the period |
— | — | — | — | ( |
) | — | ( |
) | ( |
) | |||||||||||||||||||||
| Share-based payments |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Exercise of share options |
— | ( |
) | — | — | |||||||||||||||||||||||||||
| Lapse of share options |
— | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance at June 30, 2021 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance at January 1, 2022 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
| Loss for the period |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Other comprehensive income for the period |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total comprehensive loss for the period |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||
| Share-based payments |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Exercise of share options |
— | ( |
) | — | — | ( |
) | |||||||||||||||||||||||||
| Lapse of share options |
— | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance at June 30, 2022 |
( |
) |
( |
) |
||||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
For the Six Months Ended June 30, |
||||||||
2022 |
2021 |
|||||||
(in thousands) |
||||||||
£ |
£ |
|||||||
Cash flows from operating activities |
||||||||
Loss for the period |
( |
) | ( |
) | ||||
Adjustments for: |
||||||||
Income tax credit |
( |
) | ( |
) | ||||
Amortization and depreciation |
||||||||
Finance income |
( |
) | ( |
) | ||||
Interest expense on lease liabilities |
||||||||
Share-based payments |
||||||||
Net foreign exchange (gains) losses |
( |
) | ||||||
| ( |
) | ( |
) | |||||
Movements in working capital: |
||||||||
Decrease in prepayments, accrued income and other receivables |
||||||||
Increase (decrease) in trade payables |
( |
) | ||||||
(Decrease) increase in payroll taxes, social security and accrued expenditure |
( |
) | ||||||
Movements in working capital |
( |
) | ||||||
Cash used in operations |
( |
) |
( |
) | ||||
Net income tax received |
||||||||
Net cash used in operating activities |
( |
) |
( |
) | ||||
Cash flows from investing activities |
||||||||
Interest received |
||||||||
Payments for property, plant and equipment |
( |
) | ( |
) | ||||
Payments for intangible assets |
( |
) | ( |
) | ||||
Net cash used in investing activities |
( |
) |
( |
) | ||||
Cash flows from financing activities |
||||||||
Payments for lease liabilities |
( |
) | ( |
) | ||||
Proceeds from issue of share capital |
||||||||
Net cash (used in) from financing activities |
( |
) |
||||||
Net decrease in cash and cash equivalents |
( |
) | ( |
) | ||||
Cash and cash equivalents at beginning of period |
||||||||
Effect of exchange rate changes on cash and cash equivalents |
( |
) | ||||||
Cash and cash equivalents at end of period |
||||||||
For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
(in thousands) |
||||||||||||||||
£ |
£ |
£ |
£ |
|||||||||||||
Current tax: |
||||||||||||||||
In respect of current period U.K. |
||||||||||||||||
In respect of current period U.S. |
( |
) | ( |
) | ||||||||||||
Deferred tax: |
||||||||||||||||
In respect of current period U.S. |
( |
) | ( |
) | ||||||||||||
In respect of prior period U.S. |
||||||||||||||||
Income tax credit |
||||||||||||||||
June 30, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
£ |
£ |
|||||||
Current income tax receivable |
||||||||
U.K. tax |
||||||||
U.S. tax |
||||||||
Deferred tax asset |
||||||||
U.S. deferred tax asset |
||||||||
For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
(in thousands, except per share data) |
||||||||||||||||
£ |
£ |
£ |
£ |
|||||||||||||
Loss for the period |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Basic and diluted weighted average number of shares |
||||||||||||||||
Basic and diluted loss per share |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
June 30, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
£ |
£ |
|||||||
Other non-current assets |
||||||||
June 30, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
£ |
£ |
|||||||
Cash and cash equivalents |
||||||||
Options granted on |
||||||||
March 9, 2022 |
March 9, 2022 |
|||||||
Vesting dates |
||||||||
Volatility |
% | % | ||||||
Dividend yield |
% | % | ||||||
Risk-free investment rate |
% | % | ||||||
Fair value of option at grant date |
£ | £ | ||||||
Fair value of share at grant date |
£ | £ | ||||||
Exercise price at date of grant |
£ | £ | ||||||
Lapse date |
||||||||
Expected option life (years) |
||||||||
Number of options granted |
||||||||
June 30, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
£ |
£ |
|||||||
Share capital |
||||||||
Share premium |
||||||||
June 30, 2022 |
December 31, 2021 |
|||||||
Number (in thousands) |
||||||||
Issued share capital comprises: |
||||||||
Ordinary shares of £ |
||||||||
Number of shares |
Share capital |
Share premium |
||||||||||
(in thousands) |
||||||||||||
£ |
£ |
|||||||||||
Fully paid shares: |
||||||||||||
Balance at December 31, 2021 |
||||||||||||
Issue of shares on exercise of options |
||||||||||||
Balance at June 30, 2022 |
||||||||||||
Exhibit 99.2
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of financial condition and results of operations together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commission, or the SEC, on August 17, 2022. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, and the section entitled “Risk Factors”, each of which appear in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 27, 2022 (the “Annual Report”).
We present our unaudited condensed consolidated financial statements in pounds sterling and in accordance with International Accounting Standard 34, “Interim Financial Reporting,” or IAS 34, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including generally accepted accounting principles in the United States, or U.S. GAAP.
Unless otherwise indicated or the context otherwise requires, all references to “NuCana,” the “Company,” “we,” “our,” “us” or similar terms refer to NuCana plc and its consolidated subsidiaries.
The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report and any subsequent reports that we file with the SEC.
Company Overview
We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites of anti-cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373, in combination with other agents, is in a Phase 1b/2 clinical trial in patients with metastatic colorectal cancer. NuCana has also initiated a randomized Phase 2 clinical trial of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer. In addition, NuCana has initiated a Phase 1b/2 modular clinical trial of NUC-3373 in combination with other agents, including a PD-1 inhibitor, in patients with advanced solid tumors to identify additional indications for development. NUC-7738, is a transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 clinical trial in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with a PD-1 inhibitor.
COVID-19
We continue to evaluate and assess the impact of COVID-19 on our operations and believe that this pandemic will potentially cause some delays to the timing and progress of our clinical trials.
Financial Operations Overview
Revenues
We do not have any approved products. Accordingly, we have not generated any revenue, and we do not expect to generate any revenue from the sale of any products unless and until we obtain regulatory approvals for, and commercialize any of, our product candidates. In the future, we will seek to generate revenue primarily from product sales and, potentially, regional or global collaborations with strategic partners.
Operating Expenses
We classify our operating expenses into two categories: research and development expenses and administrative expenses. Personnel costs, including salaries, benefits, bonuses and share-based payment expense, comprise a component of each of these expense categories. We allocate expenses associated with personnel costs based on the function performed by the respective employees.
Research and Development Expenses
The largest component of our total operating expenses since our inception has been costs related to our research and development activities, including the preclinical and clinical development of our product candidates.
Research and development costs are expensed as incurred. Our research and development expense primarily consists of:
| • | costs incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct preclinical studies and clinical trials; |
| • | costs related to manufacturing active pharmaceutical ingredients and drug products for preclinical studies and clinical trials; |
| • | salaries and personnel-related costs, including bonuses, benefits and any share-based payment expense, for our personnel performing research and development activities or managing those activities that have been out-sourced; |
| • | fees paid to consultants and other third parties who support our product candidate development; |
| • | costs of maintaining and defending patents; |
| • | other costs incurred in seeking regulatory approval for our product candidates; and |
| • | payments under our license agreements. |
The successful development of our ProTides is highly uncertain. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. Accordingly, we expect research and development costs to increase significantly for the foreseeable future as programs progress. However, we do not believe that it is possible at this time to accurately project total program specific expenses through commercialization. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates to offset these expenses. Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion.
The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors including:
| • | the scope, rate of progress, results and expenses of our ongoing and future clinical trials, preclinical studies and research and development activities; |
| • | the potential need for additional clinical trials or preclinical studies requested by regulatory agencies; |
| • | potential uncertainties in clinical trial enrollment rates or drop-out or discontinuation rates of patients; |
| • | competition with other drug development companies in, and the related expense of, identifying and enrolling patients in our clinical trials and contracting with third-party manufacturers for the production of the drug product needed for our clinical trials; |
| • | the achievement of milestones requiring payments under in-licensing agreements; |
| • | any significant changes in government regulation; |
| • | the terms and timing of any regulatory approvals; |
| • | the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and |
| • | the ability to market, commercialize and achieve market acceptance for any of our product candidates, if approved. |
We track research and development expenses on a program-by-program basis for both clinical-stage and preclinical product candidates. Manufacturing and non-clinical research and development expenses are assigned or allocated to individual product candidates, where appropriate.
Administrative Expenses
Administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, bonuses, benefits and share-based payment expense. Other administrative expenses include office related costs, professional fees and costs of our information systems. We anticipate that our administrative expenses will continue to increase in the future as we increase our headcount to support our continued research and development and potential commercialization of our product candidates. We also incur expenses as a public company, including expenses related to compliance with the rules and regulations of the SEC and The Nasdaq Global Select Market, additional insurance expenses, and expenses related to investor relations and other administrative and professional services.
Net Foreign Exchange Gains (Losses)
Net foreign exchange gains (losses) primarily includes gains or losses on cash held in U.S. dollars.
Finance Income
Finance income relates to interest earned on our cash and cash equivalents.
Income Tax Credit
We are subject to corporate taxation in the United Kingdom and our wholly owned U.S. subsidiary, NuCana, Inc., is subject to corporate taxation in the United States. Due to the nature of our business, since our inception we have generated losses in the United Kingdom. Our income tax credit recognized represents the sum of the research and development tax credits recoverable in the United Kingdom and in the United States, and income tax payable in the United States.
As a company that carries out extensive research and development activities, we benefit from the U.K. and U.S. research and development tax credit regimes. In the United Kingdom, we are able to surrender some of our losses for a cash rebate of up to 33.35% of eligible expenditures on qualifying research and development projects. In the United States, we are able to offset the research and development credits against corporation tax payable. Qualifying expenditures in the United Kingdom largely comprise clinical trial and manufacturing costs, employment costs for relevant staff and consumables incurred as part of research and development projects. In the United Kingdom, where we receive the larger proportion of the research and development credit, certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.68%. A large portion of costs relating to our research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.
We may not be able to continue to claim research and development tax credits in the United Kingdom in the future under the current research and development tax credit scheme because we may no longer qualify as a small or medium-sized company. However, in that scenario, we may be able to claim tax credits under a large company scheme.
Results of Operations
Comparison of the Three Months Ended June 30, 2022 and June 30, 2021
The following table summarizes the results of our operations for the three months ended June 30, 2022 and 2021.
| For the Three Months Ended June 30, |
||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| Research and development expenses |
(6,406 | ) | (8,523 | ) | ||||
| Administrative expenses |
(1,889 | ) | (2,075 | ) | ||||
| Net foreign exchange gains (losses) |
3,077 | (109 | ) | |||||
|
|
|
|
|
|||||
| Operating loss |
(5,218 | ) | (10,707 | ) | ||||
| Finance income |
132 | 35 | ||||||
|
|
|
|
|
|||||
| Loss before tax |
(5,086 | ) | (10,672 | ) | ||||
| Income tax credit |
1,194 | 1,585 | ||||||
|
|
|
|
|
|||||
| Loss for the period |
(3,892 | ) | (9,087 | ) | ||||
| Other comprehensive income (expense): |
||||||||
| Items that may be reclassified subsequently to profit or loss: |
||||||||
| Exchange differences on translation of foreign operations |
43 | (1 | ) | |||||
|
|
|
|
|
|||||
| Total comprehensive loss for the period |
(3,849 | ) | (9,088 | ) | ||||
|
|
|
|
|
|||||
Research and Development Expenses
Research and development expenses were £6.4 million for the three months ended June 30, 2022 as compared to £8.5 million for the three months ended June 30, 2021, a decrease of £2.1 million. The decrease resulted primarily from lower expenses related to clinical trials of £2.9 million in the three months ended June 30, 2022, compared with £4.5 million in the three months ended June 30, 2021 primarily due to the discontinuation of the Phase 3 clinical trial of Acelarin in March 2022. Manufacturing costs were £0.2 million in the three months ended June 30, 2022 compared with £0.8 million for the three months ended June 30, 2021, a decrease of £0.6 million. Other research and development costs increased by £0.1 million in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily due to higher personnel costs partially offset by lower share-based payment expenses.
The following table gives a breakdown of the research and development costs incurred by product candidate for the three months ended June 30, 2022 and 2021:
| For the Three Months Ended June 30, |
||||||||
| 2022 | 2021 | |||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| NUC-3373 |
2,435 | 1,453 | ||||||
| NUC-7738 |
903 | 1,133 | ||||||
| Acelarin |
2,852 | 5,332 | ||||||
| Other |
216 | 605 | ||||||
|
|
|
|
|
|||||
| 6,406 | 8,523 | |||||||
|
|
|
|
|
|||||
Administrative Expenses
Administrative expenses were £1.9 million for the three months ended June 30, 2022 as compared to £2.1 million for the three months ended June 30, 2021, a decrease of £0.2 million. The decrease was primarily related to lower share-based payment expenses, partly offset by higher professional fees.
Net Foreign Exchange Gains (Losses)
For the three months ended June 30, 2022, we reported a net foreign exchange gain of £3.1 million as compared to a net foreign exchange loss of £0.1 million for the three months ended June 30, 2021. In the three months ended June 30, 2022, the gain arose from cash balances held in U.S. dollars and the U.S. dollar appreciating relative to the U.K. pound sterling. Conversely in the three months ended June 30, 2021, the loss arose from cash balances held in U.S. dollars and the U.S. dollar depreciating relative to the U.K. pound sterling.
Finance Income
Finance income represents bank interest and was £0.1 million for the three months ended June 30, 2022 and £35,000 for the three months ended June 30, 2021. The increase in bank interest resulted from higher rates of interest being earned on cash deposits.
Income Tax Credit
The income tax credit for the three months ended June 30, 2022, which is largely comprised of U.K. research and development tax credits, amounted to £1.2 million as compared to £1.6 million for the three months ended June 30, 2021. The decrease in the income tax credit was primarily attributable to a decrease in our eligible research and development expenses.
Results of Operations
Comparison of the Six Months Ended June 30, 2022 and June 30, 2021
The following table summarizes the results of our operations for the six months ended June 30, 2022 and 2021.
| For the Six Months Ended June 30, |
||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| Research and development expenses |
(15,852 | ) | (17,229 | ) | ||||
| Administrative expenses |
(4,040 | ) | (4,179 | ) | ||||
| Net foreign exchange gains (losses) |
4,208 | (786 | ) | |||||
|
|
|
|
|
|||||
| Operating loss |
(15,684 | ) | (22,194 | ) | ||||
| Finance income |
163 | 59 | ||||||
|
|
|
|
|
|||||
| Loss before tax |
(15,521 | ) | (22,135 | ) | ||||
| Income tax credit |
3,226 | 3,287 | ||||||
|
|
|
|
|
|||||
| Loss for the period |
(12,295 | ) | (18,848 | ) | ||||
| Other comprehensive income (expense): |
||||||||
| Items that may be reclassified subsequently to profit or loss: |
||||||||
| Exchange differences on translation of foreign operations |
56 | (4 | ) | |||||
|
|
|
|
|
|||||
| Total comprehensive loss for the period |
(12,239 | ) | (18,852 | ) | ||||
|
|
|
|
|
|||||
Research and Development Expenses
Research and development expenses were £15.9 million for the six months ended June 30, 2022 as compared to £17.2 million for the six months ended June 30, 2021, reflecting a decrease of £1.3 million. The decrease resulted primarily from lower clinical trial costs of £7.8 million in the six months ended June 30, 2022, compared with £8.7 million in the six months ended June 30, 2021 largely due to the discontinuation of the Phase 3 clinical trial of Acelarin in March 2022. Manufacturing costs were £1.6 million for the six months ended June 30, 2022 compared with £1.8 million for the six months ended June 30, 2021, a decrease of £0.2 million. Other research and development costs decreased by £0.2 million in the six months ended June 30, 2022 primarily due to lower non clinical and patent costs, partly offset by higher personnel costs incurred during the period.
The following table gives a breakdown of the research and development costs incurred by product candidate for the six months ended June 30, 2022 and 2021:
| For the Six Months Ended June 30, |
||||||||
| 2022 | 2021 | |||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| NUC-3373 |
5,482 | 3,413 | ||||||
| NUC-7738 |
1,979 | 2,158 | ||||||
| Acelarin |
7,778 | 10,461 | ||||||
| Other |
613 | 1,197 | ||||||
|
|
|
|
|
|||||
| 15,852 | 17,229 | |||||||
|
|
|
|
|
|||||
Administrative Expenses
Administrative expenses were £4.0 million for the six months ended June 30, 2022 as compared to £4.2 million for the six months ended June 30, 2021, reflecting a decrease of £0.2 million. The decrease was primarily related to lower share-based payment expenses, partially offset by higher professional fees.
Net Foreign Exchange Gains (Losses)
For the six months ended June 30, 2022 we reported a net foreign exchange gain of £4.2 million as compared to a net foreign exchange loss of £0.8 million for the six months ended June 30, 2021. In the six months ended June 30, 2022, the gain arose from cash balances held in U.S. dollars and the appreciation of the U.S. dollar relative to the U.K. pound sterling. Conversely, in the six months ended June 30, 2021, the loss arose from cash balances held in U.S. dollars and reflected the depreciation of the U.S. dollar relative to the U.K. pound sterling.
Finance Income
Finance income represents bank interest and was £0.2 million for the six months ended June 30, 2022 and £0.1 million for the six months ended June 30, 2021. The increase in bank interest resulted from higher rates of interest being earned on cash deposits.
Income Tax Credit
The income tax credit for the six months ended June 30, 2022, which is largely composed of U.K. research and development tax credits, amounted to £3.2 million as compared to £3.3 million for the six months ended June 30, 2021. The decrease in the income tax credit was primarily attributable to a decrease in our eligible research and development expenses.
Liquidity and Capital Resources
Overview
Since our inception, we have incurred significant operating losses and negative cash flows. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and administrative expenses will increase in connection with conducting clinical trials and seeking marketing approval for our product candidates, as well as costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity financings, debt financings, research funding, collaborations, contract and grant revenue, or other sources.
As of June 30, 2022 and December 31, 2021, we had cash and cash equivalents of £46.5 million and £60.3 million, respectively. We do not currently have any approved products and have never generated any revenue from product sales. To date we have financed our operations primarily through the issuances of our equity securities.
In August 2021, we entered into an “at-the-market” (ATM) sales agreement with Jefferies LLC, or Jefferies, pursuant to which we may periodically sell ADSs having an aggregate offering price of up to $100.0 million through Jefferies, acting as our agent. Sales of our ADSs pursuant to this ATM program are subject to certain conditions specified in the sales agreement. In connection with entering into the agreement with Jefferies, we terminated a previous ATM sales agreement between us and Cowen and Company, LLC. Sales under the ATM program are registered on a shelf registration statement on Form F-3 that we filed with the SEC in August 2021, and which permits the offering, issuance and sale by us of up to a maximum aggregate offering price of $400.0 million of our securities, inclusive of our ADSs sold under the ATM program.
Cash Flows
Comparison of the Six Months Ended June 30, 2022 and June 30, 2021
The following table summarizes the results of our cash flows for the six months ended June 30, 2022 and 2021.
| For the Six Months Ended June 30, |
||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| Net cash used in operating activities |
(17,668 | ) | (12,931 | ) | ||||
| Net cash used in investing activities |
(125 | ) | (298 | ) | ||||
| Net cash (used in) from financing activities |
(147 | ) | 50 | |||||
|
|
|
|
|
|||||
| Net decrease in cash and cash equivalents |
(17,940 | ) | (13,179 | ) | ||||
|
|
|
|
|
|||||
Operating Activities
Net cash used in operating activities was £17.7 million for the six months ended June 30, 2022 as compared to £12.9 million for the six months ended June 30, 2021, a net increase in cash outflows of £4.8 million. Operating loss cash outflows were lower by £0.6 million for the six months ended June 30, 2022, primarily reflecting lower research and development costs. In addition, working capital outflows were £0.9 million for the six months ended June 30, 2022 as compared to working capital inflows of £0.1 million for the six months ended June 30, 2021. A tax refund of £4.3 million was received in the six months ended June 30, 2021, with no corresponding cash inflow in the six months ended June 30, 2022.
Investing Activities
Net cash used in investing activities was £0.1 million for the six months ended June 30, 2022 as compared to net cash used in investing activities of £0.3 million for the six months ended June 30, 2021, primarily reflecting an increase in interest received for the six months ended June 30, 2022.
Financing Activities
Net cash used in financing activities was £0.1 million for the six months ended June 30, 2022 as compared to net cash from financing activities of £0.1 million for the six months ended June 30, 2021, reflecting a decrease in the proceeds from the issue of share capital, related to the exercise of share options.
Operating and Capital Expenditure Requirements
We have not achieved profitability on an annual basis since our inception, and we expect to incur net losses in the future. We expect that our operating expenses will increase as we continue to invest in our research and development programs, exploit our ProTide pipeline and build out our organization with additional employees.
We believe that our existing capital resources will be sufficient to fund our operations, including currently anticipated research and development activities and planned capital spending, for at least the next 12 months.
Our future funding requirements will depend on many factors, including but not limited to:
| • | the scope, rate of progress and cost of our clinical trials, preclinical programs and other related activities; |
| • | the extent of success in our early preclinical and clinical stage research programs, which will determine the amount of funding required to further the development of our product candidates; |
| • | the progress that we make in developing new product candidates based on our proprietary ProTide technology; |
| • | the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop; |
| • | the costs involved in filing and prosecuting patent applications and enforcing and defending potential patent claims; |
| • | the outcome, timing and cost of regulatory approvals of our ProTide product candidates; |
| • | the cost and timing of establishing sales, marketing and distribution capabilities; |
| • | the costs of hiring additional skilled employees to support our continued growth and the related costs of leasing additional office space; and |
| • | developments related to COVID-19 and its impact on the costs and timing associated with the conduct of our clinical trials, preclinical programs and other related activities. |
Legal Proceedings
From time to time, we may be party to litigation that arises in the ordinary course of our business. Other than as discussed below, we do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows.
In 2018, we were granted a European patent from the European Patent Office (EPO), EP 2955190, that covers the composition of matter of a small genus of phosphoramidate nucleotide compounds that includes sofosbuvir which is a key component of the products Sovaldi®, Harvoni®, Epclusa® and Vosevi®; leading drugs for the treatment of hepatitis C sold by Gilead Sciences, Inc. and its affiliates. Sofosbuvir and our drug Acelarin share a similar chemical structure, and sofosbuvir is covered by the claims in our patent, which predates Gilead’s patent on sofosbuvir by several years. Later in 2018, Gilead filed an Opposition to our patent at the EPO in an attempt to have it revoked. In February 2021, the EPO Opposition Division upheld the patent with amended patent claims that still cover sofosbuvir. We believe this decision is correct, and is a further confirmation of the ground-breaking work of our late Chief Scientific Officer, Professor Christopher McGuigan, as the creator of the ProTide prodrug strategy to deliver nucleotides for the treatment of patients with cancer or viral infections. In June 2021, Gilead filed an appeal against the decision of the Opposition Division to the EPO Technical Boards of Appeal. We also filed an appeal against the decision by the Opposition Division to only allow the patent in an amended form. There can be no assurance as to the outcome of such an appeal. The Boards of Appeal could disagree with the Opposition Division, in whole or part, and revoke our patent, or agree with the Opposition Division and uphold our patent.
A European patent can be asserted against infringers, in this case European affiliates of Gilead Sciences, Inc., in national courts in Europe, even before a final decision of the EPO Technical Boards of Appeal, and can also be challenged in the national courts of some jurisdictions. Following our European patent being upheld by the EPO Opposition Division, in February 2021, Gilead Sciences, Inc. and Gilead Sciences Limited filed a lawsuit against us in the Patents Court of the High Court of Justice of England and Wales requesting revocation of the UK part of EP 2955190. In March 2021, we filed a counterclaim against Gilead Sciences, Inc. and Gilead Sciences Limited in those proceedings, alleging infringement of our patent resulting from acts including the sale of Sovaldi, as well as its combination products Harvoni, Vosevi and Epclusa, in the United Kingdom.
Separately, in April 2021, we initiated legal proceedings against Gilead Sciences Ireland UC and Gilead Sciences GmbH in the German Regional Court of Dusseldorf (“RC Dusseldorf”) for patent infringement for the sale of Sovaldi as well as its combination products Harvoni, Vosevi and Epclusa in Germany. In July 2022, following a comprehensive hearing in May 2022, the RC Dusseldorf issued a judgment that the two Gilead entities infringe our composition of matter claims in EP 2955190 through their sales of Sovaldi, Harvoni, Vosevi and Epclusa in Germany, inter alia ordering them to cease and desist and declaring that they are liable for damages. The decision of the RC Dusseldorf only applies to Germany and the two Gilead entities have appealed the decision. In April 2022, Gilead Sciences Ireland UC and Gilead Sciences GmbH also filed an action for a compulsory license before the German Federal Patent Court. If granted, such compulsory license would allow the two Gilead entities to continue marketing their sofosbuvir-containing products in Germany in return for payment by Gilead of a royalty to be determined by the Federal Patent Court. We intend to vigorously defend our patent rights and the foundational work of Professor McGuigan.
The appeal of the decision upholding our patent by the EPO Opposition Division, the continuing litigation in Germany and before the UK Patents Court with Gilead, and potential future infringement or validity litigation in Europe with Gilead may subject us to significant legal expense and may be a distraction to management. There can be no assurance that our patent on sofosbuvir will be upheld as valid and infringed by any national court in Europe, or upheld as valid by the European Technical Boards of Appeal. See “Risk Factors — Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.” in our Annual Report on Form 20-F for the year ended December 31, 2021.
This litigation does not affect the patent protection on any of our product candidates, which are covered by separate patents that are not involved in this litigation.
Exhibit 99.3
NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023
Well Capitalized with Anticipated Cash Runway into 2025
Edinburgh, United Kingdom, August 17, 2022 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
As of June 30, 2022, NuCana had cash and cash equivalents of £46.5 million compared to £52.6 million as of March 31, 2022 and £60.3 million at December 31, 2021. NuCana continues to advance its various clinical programs and reported a net loss of £3.9 million for the quarter ended June 30, 2022, as compared to a net loss of £9.1 million for the quarter ended June 30, 2021. Basic and diluted loss per share was £0.07 for the quarter ended June 30, 2022, as compared to £0.17 per share for the quarter ended June 30, 2021.
“During the first half of the year, we have remained focused on the rapid and efficient implementation of our development plans,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “In the past few months, we initiated two studies: NuTide:323, a randomized Phase 2 trial of NUC-3373 in combination with other agents for the treatment of second-line patients with colorectal cancer; and NuTide:303, a Phase 1b/2 study of NUC-3373 in combination with other agents including the PD-1 inhibitor pembrolizumab, for the treatment of patients with solid tumors. We also continue to enroll patients in the Phase 1b/2 NuTide:302 study of NUC-3373 in patients with colorectal cancer and the Phase 2 monotherapy part of the NuTide:701 study of NUC-7738 in patients with solid tumors, which will expand to include combination with pembrolizumab.”
Mr. Griffith continued: “From a corporate perspective, we recently announced that the Regional Court of Dusseldorf issued a judgement that Gilead’s sofosbuvir infringes our European composition-of-matter patent. We will continue to defend our patent rights and the foundational work of our late Chief Scientific Officer, Professor Chris McGuigan. Additionally, we regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.”
Mr. Griffith concluded: “We have provided multiple data updates for both NUC-3373 and NUC-7738 that demonstrate the potential of our ProTides to offer more effective and safer treatment options for patients with cancer. These data have highlighted the compelling anti-cancer activity and favorable safety profiles and pharmacokinetic properties of our product candidates. With an anticipated cash runway into 2025 and through numerous key milestones for both NUC-3373 and NUC-7738, we remain on track to provide a number of data updates over the coming year as we continue to advance our pipeline.”
Anticipated Milestones: H2 2022 and H1 2023
| • | NUC-3373 (a ProTide transformation of 5-FU) |
In the second half of 2022, NuCana expects to:
| • | Commence enrollment in the randomized, controlled Phase 2 (NuTide:323) study of NUC-3373 in combination with other agents for the second-line treatment of patients with colorectal cancer; |
| • | Commence enrollment in the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with other agents, including the PD-1 inhibitor pembrolizumab, in patients with solid tumors to identify additional indications for development; |
| • | Expand the Phase 1b/2 (NuTide:302) study of NUC-3373 in colorectal cancer patients, and evaluate NUC-3373-based regimens in combination with bevacizumab in second-line patients with colorectal cancer; |
| • | Announce data from the Phase 1b/2 (NuTide:302) study of NUC-3373 combined with leucovorin, irinotecan and bevacizumab in patients with colorectal cancer; and |
| • | Announce data from the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with other agents in patients with solid tumors to identify additional indications for development. |
In the first half of 2023, NuCana expects to:
| • | Announce data from the Phase 1b/2 (NuTide:302) study of NUC-3373 combined with leucovorin, irinotecan and bevacizumab in patients with colorectal cancer; and |
| • | Announce data from the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with other agents in patients with solid tumors to identify additional indications for development. |
| • | NUC-7738 (a ProTide transformation of 3’-deoxyadenosine) |
In the second half of 2022, NuCana expects to:
| • | Announce data from the Phase 1 part of the NuTide:701 study of NUC-7738 in patients with solid tumors; |
| • | Commence enrollment in the Phase 2 part of the NuTide:701 study of NUC-7738 in combination with the PD-1 inhibitor pembrolizumab, in patients with solid tumors; and |
| • | Announce data from the Phase 2 part of the NuTide:701 study of NUC-7738 in patients with solid tumors. |
In the first half of 2023, NuCana expects to:
| • | Announce data from the Phase 1 part of the NuTide:701 study of NUC-7738 in patients with solid tumors; and |
| • | Announce data from the Phase 2 part of the NuTide:701 study of NUC-7738 in patients with solid tumors. |
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373, in combination with other agents, is in a Phase 1b/2 study in patients with metastatic colorectal cancer. NuCana has also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer. In addition, NuCana has initiated a Phase 1b/2 modular study of NUC-3373 in combination with other agents, including a PD-1 inhibitor, in patients with advanced solid tumors to identify additional indications for development. NUC-7738 is a transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with a PD-1 inhibitor.
Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash, cash equivalents and marketable securities to fund its planned operations into 2025. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 27, 2022, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| £ | £ | £ | £ | |||||||||||||
| Research and development expenses |
(6,406 | ) | (8,523 | ) | (15,852 | ) | (17,229 | ) | ||||||||
| Administrative expenses |
(1,889 | ) | (2,075 | ) | (4,040 | ) | (4,179 | ) | ||||||||
| Net foreign exchange gains (losses) |
3,077 | (109 | ) | 4,208 | (786 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating loss |
(5,218 | ) | (10,707 | ) | (15,684 | ) | (22,194 | ) | ||||||||
| Finance income |
132 | 35 | 163 | 59 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before tax |
(5,086 | ) | (10,672 | ) | (15,521 | ) | (22,135 | ) | ||||||||
| Income tax credit |
1,194 | 1,585 | 3,226 | 3,287 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss for the period |
(3,892 | ) | (9,087 | ) | (12,295 | ) | (18,848 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted loss per share |
(0.07 | ) | (0.17 | ) | (0.24 | ) | (0.36 | ) | ||||||||
Unaudited Condensed Consolidated Statements of Financial Position
| June 30, 2022 |
December 31, 2021 |
|||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| Assets |
||||||||
| Non-current assets |
||||||||
| Intangible assets |
2,469 | 2,410 | ||||||
| Property, plant and equipment |
613 | 851 | ||||||
| Deferred tax asset |
80 | 60 | ||||||
| Other non-current assets |
2,604 | 2,540 | ||||||
|
|
|
|
|
|||||
| 5,766 | 5,861 | |||||||
|
|
|
|
|
|||||
| Current assets |
||||||||
| Prepayments, accrued income and other receivables |
3,934 | 4,161 | ||||||
| Current income tax receivable |
10,403 | 7,188 | ||||||
| Cash and cash equivalents |
46,528 | 60,264 | ||||||
|
|
|
|
|
|||||
| 60,865 | 71,613 | |||||||
|
|
|
|
|
|||||
| Total assets |
66,631 | 77,474 | ||||||
|
|
|
|
|
|||||
| Equity and liabilities |
||||||||
| Capital and reserves |
||||||||
| Share capital and share premium |
143,138 | 143,137 | ||||||
| Other reserves |
74,644 | 72,137 | ||||||
| Accumulated deficit |
(161,747 | ) | (149,726 | ) | ||||
|
|
|
|
|
|||||
| Total equity attributable to equity holders of the Company |
56,035 | 65,548 | ||||||
|
|
|
|
|
|||||
| Non-current liabilities |
||||||||
| Provisions |
46 | 46 | ||||||
| Lease liabilities |
118 | 164 | ||||||
|
|
|
|
|
|||||
| 164 | 210 | |||||||
|
|
|
|
|
|||||
| Current liabilities |
||||||||
| Trade payables |
2,141 | 1,829 | ||||||
| Payroll taxes and social security |
170 | 170 | ||||||
| Accrued expenditure |
8,003 | 9,510 | ||||||
| Lease liabilities |
118 | 207 | ||||||
|
|
|
|
|
|||||
| 10,432 | 11,716 | |||||||
| Total liabilities |
10,596 | 11,926 | ||||||
|
|
|
|
|
|||||
| Total equity and liabilities |
66,631 | 77,474 | ||||||
|
|
|
|
|
|||||
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| (in thousands) | ||||||||
| £ | £ | |||||||
| Cash flows from operating activities |
||||||||
| Loss for the period |
(12,295 | ) | (18,848 | ) | ||||
| Adjustments for: |
||||||||
| Income tax credit |
(3,226 | ) | (3,287 | ) | ||||
| Amortization and depreciation |
470 | 444 | ||||||
| Finance income |
(163 | ) | (59 | ) | ||||
| Interest expense on lease liabilities |
5 | 10 | ||||||
| Share-based payments |
2,741 | 3,615 | ||||||
| Net foreign exchange (gains) losses |
(4,283 | ) | 759 | |||||
|
|
|
|
|
|||||
| (16,751 | ) | (17,366 | ) | |||||
| Movements in working capital: |
||||||||
| Decrease in prepayments, accrued income and other receivables |
295 | 424 | ||||||
| Increase (decrease) in trade payables |
312 | (560 | ) | |||||
| (Decrease) increase in payroll taxes, social security and accrued expenditure |
(1,524 | ) | 269 | |||||
|
|
|
|
|
|||||
| Movements in working capital |
(917 | ) | 133 | |||||
|
|
|
|
|
|||||
| Cash used in operations |
(17,668 | ) | (17,233 | ) | ||||
|
|
|
|
|
|||||
| Net income tax received |
— | 4,302 | ||||||
|
|
|
|
|
|||||
| Net cash used in operating activities |
(17,668 | ) | (12,931 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities |
||||||||
| Interest received |
161 | 58 | ||||||
| Payments for property, plant and equipment |
(10 | ) | (37 | ) | ||||
| Payments for intangible assets |
(276 | ) | (319 | ) | ||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(125 | ) | (298 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from financing activities |
||||||||
| Payments of lease liabilities |
(148 | ) | (148 | ) | ||||
| Proceeds from issue of share capital |
1 | 198 | ||||||
|
|
|
|
|
|||||
| Net cash (used in) from financing activities |
(147 | ) | 50 | |||||
|
|
|
|
|
|||||
| Net decrease in cash and cash equivalents |
(17,940 | ) | (13,179 | ) | ||||
| Cash and cash equivalents at beginning of period |
60,264 | 87,356 | ||||||
|
|
|
|
|
|||||
| Effect of exchange rate changes on cash and cash equivalents |
4,204 | (756 | ) | |||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
46,528 | 73,421 | ||||||
|
|
|
|
|
|||||
For more information, please contact:
NuCana plc
Hugh S. Griffith
Chief Executive Officer
+44 131 357 1111
info@nucana.com
Westwicke, an ICR Company
Chris Brinzey
+1 339-970-2843
chris.brinzey@westwicke.com
RooneyPartners
Marion Janic
+1 212-223-4017
mjanic@rooneyco.com